AstraZeneca Expands Lymphoma Pipeline With TeneoTwo Acquisition

Enters Crowded Bispecific Field

AstraZeneca has bought TeneoTwo and its bispecific asset TNB-486 to enlarge its hemato-oncology pipeline but the UK major is still a long way off being a key player in the field.

AZ building
AstraZeneca's Calquence is a major success in non-Hodgkin's lymphoma, but bispecifics are expected to play a major part in future therapy. • Source: Shutterstock

AstraZeneca is to spend $100m upfront to acquire TeneoTwo and its T-cell engager TNB-486 as it looks to build its presence in hemato-oncology.

TeneoTwo is one of several bispecific-focused companies established by father and son duo Roland and Ben Buelow, having already sold...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip